Why the study?
Does diabetes mellitus attenuate regression of ECG left ventricular hypertrophy and alter its prognostic value in hypertensive patients receiving antihypertensive therapy?
Population
9,193 hypertensive patients with ECG left ventricular hypertrophy enrolled in the Losartan Intervention For…
Design
Cohort
Follow-up
mean 4.8+/-0.9 years
Key result
Diabetes mellitus in hypertensive patients was associated with significantly less regression of ECG left ventricular hypertrophy during antihypertensive therapy than no diabetes (-138 vs -204 mm.ms; P<0.001).
Authors
Loading...
Attenuated ECG LVH regression questions its surrogate value in diabetic hypertensives; leaves open impact on cardiovascular outcomes.
Cohort (n=9,193)
Does diabetes mellitus attenuate regression of ECG left ventricular hypertrophy and alter its prognostic value in hypertensive patients receiving antihypertensive therapy?
Absolute Event Rate: -138% vs -204%
p-value: p=<0.001
In hypertensive patients, diabetes attenuates the regression of ECG LVH during antihypertensive therapy, and LVH regression is less useful as a surrogate marker for cardiovascular outcomes in this population.
Okin et al. (2006) conducted a cohort in Hypertension (n=9,193). Diabetes mellitus (exposure) vs. No diabetes mellitus was evaluated on Regression of ECG left ventricular hypertrophy (Cornell voltage-duration product) (p=<0.001). Diabetes mellitus in hypertensive patients was associated with significantly less regression of ECG left ventricular hypertrophy during antihypertensive therapy than no diabetes (-138 vs -204 mm.ms; P<0.001).